Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
New findings sits at the center of this dementia and brain health question.
Recent breakthroughs in medical research are fundamentally changing how doctors understand and classify disease progression across multiple conditions. The most significant shift is in Alzheimer’s disease, where a new 2024 staging system has replaced previous diagnostic categories with a more precise biological and clinical framework. For the first time, doctors can now categorize Alzheimer’s using four biological stages (A-D) based on actual beta-amyloid and tau pathology, combined with seven clinical stages (0-6) reflecting symptom severity—giving patients and families a clearer picture of where someone stands in their disease journey. Beyond Alzheimer’s, clarified staging systems are emerging across chronic kidney disease, leukemia, and other serious health conditions.
These new classifications aren’t just academic refinements; they’re enabling doctors to predict progression rates, customize treatments, and help patients make informed decisions about their care. For example, a patient receiving a diagnosis of stage 3b chronic kidney disease now has access to value-based care interventions that can reduce their disease decline by more than 77 percent—information that simply wasn’t available in previous diagnostic frameworks. This shift represents a move away from broad disease categories toward precision medicine—tailoring diagnosis and treatment based on specific biological markers and individual disease progression patterns. Understanding these new staging systems is essential for anyone facing a dementia diagnosis, managing chronic kidney disease, or supporting a loved one through these conditions.
Table of Contents
- How Are Disease Stages Being Reclassified?
- Advances in Early Detection and Diagnosis
- Prevention and Risk Reduction Breakthroughs
- How Staging Improves Patient Care and Management
- Limitations and Ongoing Challenges in Disease Classification
- Disease-Specific Advances: Leukemia and Cellular Disease Modeling
- The Future of Disease Classification and Precision Medicine
- Conclusion
- Frequently Asked Questions
How Are Disease Stages Being Reclassified?
The new Alzheimer’s staging system introduced in 2024 marks the most comprehensive overhaul of disease classification in decades. Rather than relying solely on memory complaints or cognitive testing, the system now uses objective biological markers—specifically the presence and levels of beta-amyloid and tau proteins in the brain—to establish a biological diagnosis that can be confirmed years before clinical symptoms appear. This four-stage biological classification (stages A through D) runs parallel to a seven-stage clinical scale, allowing doctors to distinguish between people who have biological evidence of disease but no symptoms, those experiencing mild cognitive changes, and those with moderate to severe dementia.
This dual-stage approach means that two patients with the same symptoms might receive very different diagnoses and treatment plans depending on their underlying biomarker profiles. A person in biomarker stage B (amyloid accumulation without tau) faces a different trajectory and treatment response than someone in stage C (both amyloid and tau present). The Chronic Kidney Disease Stages similarly have been refined under updated 2024 KDIGO guidelines, which now emphasize more granular risk assessment and individualized intervention strategies based on glomerular filtration rate (GFR) and urine albumin levels.
Advances in Early Detection and Diagnosis
The development of FDA-cleared blood tests represents one of the most practical advances in disease staging. In 2025, the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio became the first blood-based biomarker test cleared for clinical use in Alzheimer’s diagnosis, eliminating the need for invasive cerebrospinal fluid tests or expensive PET scans. This means a patient can now receive a biomarker-confirmed diagnosis during a routine office visit, with results available within days rather than months. The test’s accuracy in predicting which cognitively normal individuals will develop Alzheimer’s within five to ten years has shifted the entire diagnostic timeline.
However, access to these tests remains uneven. While the blood tests are less expensive than PET imaging, they’re still not universally covered by insurance, and specialist interpretation of results varies. Additionally, a positive biomarker doesn’t guarantee someone will develop dementia in their lifetime—some people with documented Alzheimer’s pathology die of other causes before showing cognitive symptoms. The technology is transformative, but patients and families should understand that a positive test indicates biological disease, not a certain future.
Prevention and Risk Reduction Breakthroughs
One of the more unexpected findings in recent dementia research is the relationship between shingles vaccination and dementia prevention. A large Welsh population study found that people vaccinated against shingles were 20 percent less likely to develop Alzheimer’s disease or other forms of dementia over seven years. While researchers are still investigating the mechanism—potentially involving reduced neuroinflammation triggered by varicella-zoster virus—the finding has led to new conversations about vaccines as a prevention strategy for cognitive decline.
Equally intriguing is NIH-funded research identifying lithium deficiency as a potential causative factor in Alzheimer’s disease development. Lithium, a naturally occurring mineral found in varying concentrations in water and soil across different geographic regions, appears to play a neuroprotective role. People living in areas with naturally higher lithium levels in their drinking water show lower dementia rates. This opens the door to potential prevention strategies beyond pharmaceutical interventions and suggests that disease staging might eventually include assessment of micronutrient status.
How Staging Improves Patient Care and Management
Precise disease staging directly translates to better outcomes and reduced disease progression. The most compelling evidence comes from chronic kidney disease management, where value-based care interventions tailored to specific disease stages resulted in a 77.2 percent reduction in the median decline rate for stage 3b CKD patients and 65.2 percent reduction for stage 4 patients. This represents a fundamental shift—instead of a one-size-fits-all approach to kidney disease, treatment becomes individualized based on exactly where someone’s disease sits in its progression.
In Alzheimer’s care, staging clarity means that someone in a preclinical stage (biomarkers present, no symptoms) might pursue lifestyle interventions and risk factor management, while a person in stage 4 (severe dementia) might focus on symptom management and quality of life. The tradeoff is that more precise staging also requires more testing and specialist consultation, which can be time-consuming and costly for patients already managing complex health conditions. Families sometimes feel overwhelmed by the additional diagnostic detail, preferring simpler explanations to the nuanced staging categories now available.
Limitations and Ongoing Challenges in Disease Classification
Despite these advances, significant limitations remain in how diseases are staged across different medical conditions. Not all dementia types have equally robust staging systems—vascular dementia, Lewy body dementia, and frontotemporal dementia lack the same level of biomarker validation as Alzheimer’s. This means a patient with non-Alzheimer’s dementia might still receive a vague or preliminary diagnosis even as their Alzheimer’s-diagnosed cousin gets precise biomarker information.
Geographic variation in access to advanced testing creates a two-tiered diagnostic system. Major medical centers can offer comprehensive biomarker testing, advanced imaging, and specialist consultation, while rural and underserved areas may only have access to basic cognitive screening. Additionally, the cost of these new diagnostic tools isn’t yet fully absorbed into standard healthcare coverage, meaning some patients will receive earlier, more precise diagnoses than others based on insurance status and location. Healthcare systems are still developing protocols for how to use these new staging systems to guide treatment decisions, creating inconsistency in how staging information translates to actual care changes.
Disease-Specific Advances: Leukemia and Cellular Disease Modeling
New technology developed at the Tisch Cancer Center demonstrates how disease staging and modeling can advance through cellular reprogramming. Researchers have developed the ability to convert acute myeloid leukemia patient cells into stem cells that can then be directed to mimic different disease progression stages. This means leukemia—a disease that was previously difficult to study outside the human body—can now be modeled in real-time to understand how it develops from early stage to advanced disease.
This breakthrough has implications beyond leukemia research. The same cellular reprogramming technology is being adapted for other cancers and blood disorders, potentially enabling a future where patient cells are used to test how their specific disease will respond to different treatments before those treatments are actually given. For disease staging specifically, this technology clarifies the molecular and cellular changes that define progression from one stage to the next, information that helps refine staging criteria and improve accuracy of stage classification.
The Future of Disease Classification and Precision Medicine
As biomarker technology continues to evolve, disease staging will likely become even more granular and individualized. The combination of blood tests, genetic profiling, and advanced imaging suggests that future disease classifications will move away from broad categories toward continuous spectrum assessments. Rather than declaring someone “stage 2” Alzheimer’s disease, clinicians might describe specific levels of different biomarkers, painting a more detailed picture of individual disease biology.
The research pipeline suggests that preventive strategies based on staging will expand significantly. If the shingles vaccine association holds up in larger studies, and if lithium’s neuroprotective role can be confirmed through randomized trials, future dementia prevention might begin with population screening for staging biomarkers, followed by targeted interventions for those at high risk. The ultimate goal is intervening as early as possible—ideally when disease biomarkers are present but before symptoms begin, when the window for changing disease trajectory is potentially widest.
Conclusion
The clarification of disease stages across Alzheimer’s disease, chronic kidney disease, and other serious health conditions represents a watershed moment in medicine. New biological staging systems, FDA-cleared blood tests, and evidence-based prevention strategies are replacing outdated diagnostic approaches with precision frameworks that better predict disease progression and guide individualized treatment. For patients and families, this means more information, better understanding of what to expect, and potentially more time to intervene before symptoms become severe.
The path forward requires ensuring that these advances don’t create disparities—that precise staging becomes available to all patients regardless of geography or insurance status, not just those in major medical centers. If you or a loved one is facing a dementia diagnosis, chronic kidney disease, or other serious condition, ask your healthcare provider about new staging systems and biomarker testing. Understanding which stage you’re in and what that means for your specific disease trajectory is increasingly powerful information for making informed decisions about your care.
Frequently Asked Questions
What’s the difference between the biological and clinical stages in the new Alzheimer’s system?
Biological stages (A-D) measure actual brain pathology—the presence of amyloid and tau proteins—regardless of whether someone has symptoms. Clinical stages (0-6) measure cognitive function and symptom severity. Someone can be in biomarker stage C (pathology present) while in clinical stage 1 (no cognitive symptoms).
Can a blood test diagnose Alzheimer’s disease?
The FDA-cleared Lumipulse blood test can confirm biological evidence of Alzheimer’s pathology, but diagnosis still requires correlation with cognitive testing and symptom evaluation. A positive biomarker test doesn’t automatically mean someone has Alzheimer’s disease—it means they have pathological changes consistent with Alzheimer’s.
Does getting the shingles vaccine prevent dementia?
Population studies suggest a 20 percent risk reduction, but the vaccine is not a guarantee against dementia. Vaccination appears to be one factor among many that influences dementia risk, alongside cardiovascular health, cognitive engagement, education, and genetics.
How do the new staging systems change treatment decisions?
Precise staging allows doctors to tailor interventions based on disease progression stage and expected trajectory. For chronic kidney disease, stage-specific value-based care interventions can reduce disease decline by 65-77 percent, compared to less targeted approaches.
Will genetic testing become part of standard disease staging?
It already is for some conditions, and its role is expanding. The leukemia cellular reprogramming technology suggests genetics will increasingly inform both disease classification and individualized treatment selection.
If I have biological markers but no symptoms, should I start treatment?
This is a personal decision to discuss with your doctor. For Alzheimer’s, current guidelines suggest some may benefit from early treatment, while others choose to monitor with regular testing. The decision depends on biomarker levels, age, other health conditions, and personal values.
You Might Also Like
- Research Improves Understanding of Disease
- New Findings Suggest Protective Effects
- New Findings Suggest Preventive Monitoring
For more, see Alzheimer’s Association — clinical trials.
